Progress In Microbes & Molecular Biology, Journal Year: 2025, Volume and Issue: 8(1)
Published: Jan. 15, 2025
Depression affects approximately 280 million people worldwide, representing a significant public health burden. It is characterized by persistent sadness, anhedonia, fatigue, sleep disturbances, cognitive dysfunction, and in severe cases, suicidal ideation. The pathophysiology often attributed to neurotransmitter imbalances, hypothalamic-pituitary-adrenal (HPA) axis inflammation. Recently, the gut-brain has garnered attention for its role mood regulation, suggesting that probiotic supplementation may influence depressive symptoms through gut microbiome modulation. Therefore, this review examines recent findings research gaps regarding efficacy of probiotics managing clinically diagnosed depression. Emerging demonstrates daily from 3×109 CFU 9×1011 four eight weeks combination with antidepressants effective improving symptoms. Effective formulations commonly included Bifidobacteria, Lactobacilli, Lactococcus lactis, Streptococcus thermophilus. Nevertheless, remain, particularly concerning mechanistic pathways, comparative effectiveness, impact across different demographics probiotics. Furthermore, long-term effects use antidepressants, their reducing antidepressant side effects, combined psychotherapy are largely understudied. Addressing these standardized methodologies will enhance evaluations strains optimize microbiome-based treatment regimens, ultimately improve mental outcomes depression management. Graphical abstract. Summary future directions determine
Language: Английский